Targeting the TGFβ pathway with galunisertib, a TGFβRI SMI, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint inhibition. (4th November 2015) - Schaer, David; Li, Yanxia; Castaneda, Stephen; Inigo, Ivan; Surguladze, David; Xu, Xiaohong; Nugent, Desiree; Murphy, Mary; Hall, Gerald; Benhadji, Karim; Guba, Susan; Li, Yiwen; et al.